GlassScriptPhysician profile
Staci M Bubp
NPI 1992322838
$1,081.32
in general payments reported to CMS, 2019-2025
12 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $424 · 2022: $343 · 2023: $125 · 2024: $50.00 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $249.63 | 2023-2025 | |
| Biodelivery Sciences International, INC. | $231.20 | 2021 | |
| Medtronic, INC. | $174.69 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $107.00 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $100.99 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.02 | 2021 | |
| Intra-Sana Laboratories | $50.00 | 2024 | Reltone 400 Mg, Reltone 200 Mg |
| Tersera Therapeutics LLC | $35.99 | 2022 | |
| Grt US Holding, INC. | $26.81 | 2021-2022 | |
| Redhill Biopharma INC. | $19.50 | 2021 | |
| Pfizer INC. | $15.82 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $14.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Bubp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.